TW200502246A - Vaccine - Google Patents

Vaccine

Info

Publication number
TW200502246A
TW200502246A TW092131802A TW92131802A TW200502246A TW 200502246 A TW200502246 A TW 200502246A TW 092131802 A TW092131802 A TW 092131802A TW 92131802 A TW92131802 A TW 92131802A TW 200502246 A TW200502246 A TW 200502246A
Authority
TW
Taiwan
Prior art keywords
present
hcv
treatment
methods
relates
Prior art date
Application number
TW092131802A
Other languages
English (en)
Inventor
Sara Brett
Paul Andrew Hamblin
Louise Ogilvie
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of TW200502246A publication Critical patent/TW200502246A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
TW092131802A 2002-11-15 2003-11-13 Vaccine TW200502246A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0226722.7A GB0226722D0 (en) 2002-11-15 2002-11-15 Vaccine

Publications (1)

Publication Number Publication Date
TW200502246A true TW200502246A (en) 2005-01-16

Family

ID=9947928

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092131802A TW200502246A (en) 2002-11-15 2003-11-13 Vaccine

Country Status (21)

Country Link
US (4) US20060135451A1 (zh)
EP (2) EP1560844A1 (zh)
JP (2) JP2006518331A (zh)
KR (2) KR20050085010A (zh)
CN (2) CN1738833A (zh)
AR (1) AR041964A1 (zh)
AU (2) AU2003288084A1 (zh)
BR (2) BR0316244A (zh)
CA (2) CA2504654A1 (zh)
CO (1) CO5700833A2 (zh)
GB (1) GB0226722D0 (zh)
IS (2) IS7830A (zh)
MA (2) MA27700A1 (zh)
MX (2) MXPA05005202A (zh)
NO (2) NO20052149L (zh)
NZ (2) NZ539998A (zh)
PL (2) PL376882A1 (zh)
RU (2) RU2363492C2 (zh)
TW (1) TW200502246A (zh)
WO (2) WO2004046175A1 (zh)
ZA (2) ZA200503802B (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
CN102614510A (zh) * 2004-10-18 2012-08-01 全球免疫股份有限公司 基于酵母的对慢性丙型肝炎感染的治疗
CA2636032C (en) * 2006-01-04 2016-04-12 Novartis Vaccines And Diagnostics, Inc. Activation of hcv-specific t cells
CA2645177A1 (en) * 2006-03-09 2007-09-13 Transgene S.A. Hepatitis c virus non structural fusion protein
AU2007345768B2 (en) * 2006-07-27 2013-08-01 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
EP2044224A4 (en) * 2006-07-27 2011-04-13 Ligocyte Pharmaceuticals Inc CHIMERIC VIRUS TYPE PARTICLES
KR100759106B1 (ko) * 2007-02-14 2007-09-19 이화여자대학교 산학협력단 초미세 전기기계 시스템 미러에서 미러 판을 정전 구동부와 결합하는 방법
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
US20110091495A1 (en) * 2008-04-22 2011-04-21 Rutgers, The State University Of New Jersey Hcv e2 construct compositions and methods
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
AU2009273949A1 (en) * 2008-07-24 2010-01-28 Aduro Biotech Compositions and methods for the treatment of hepatitis C
WO2010033841A1 (en) 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
CN101748151B (zh) * 2008-12-19 2012-10-17 深圳市源兴生物医药科技有限公司 一种重组人丙肝病毒抗原腺病毒载体及其应用
JP2010168288A (ja) * 2009-01-20 2010-08-05 Yokohama City Univ 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強
CN102753582A (zh) 2009-11-03 2012-10-24 莱戈赛特医药股份有限公司 嵌合RSV-F多肽、和慢病毒或α-反转录病毒GAG基VLP
CN102233137B (zh) * 2010-04-30 2013-02-20 北京凯因科技股份有限公司 一种用于治疗乙型肝炎的重组质粒dna疫苗组合物
AU2014221143B2 (en) * 2013-02-21 2019-02-07 Turnstone Limited Partnership Vaccine composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
EP0789563B8 (en) * 1994-10-05 2004-11-17 Apollon, Inc. Hepatitis virus b and c vaccines
WO1996037606A1 (en) * 1995-05-22 1996-11-28 Bionova Corporation Compositions and methods for the diagnosis of, and vaccination against, hepatitis c virus (hcv)
CA2257137A1 (en) * 1996-06-11 1997-12-18 Merck & Co., Inc. Synthetic hepatitis c genes
US7052696B2 (en) * 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
CA2379235A1 (en) * 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services, Centers For Disease Co Antigenic epitopes and mosaic polypeptides of hepatitis c virus proteins
EP1232267B1 (en) * 1999-10-27 2013-03-20 Novartis Vaccines and Diagnostics, Inc. Activation of hcv-specific t cells
CN101684146A (zh) * 1999-11-24 2010-03-31 诺华疫苗和诊断公司 新颖的hcv非结构多肽
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine

Also Published As

Publication number Publication date
RU2363492C2 (ru) 2009-08-10
US20060246090A1 (en) 2006-11-02
MXPA05005203A (es) 2006-01-27
RU2005113691A (ru) 2006-01-27
BR0316244A (pt) 2005-10-04
CN1738833A (zh) 2006-02-22
EP1560845A1 (en) 2005-08-10
CA2504715A1 (en) 2004-06-03
US20060135451A1 (en) 2006-06-22
NO20052136D0 (no) 2005-05-02
GB0226722D0 (en) 2002-12-24
WO2004046176A1 (en) 2004-06-03
AU2003288084A1 (en) 2004-06-15
NO20052136L (no) 2005-07-11
NO20052149D0 (no) 2005-05-02
US20090104231A1 (en) 2009-04-23
CN1738834A (zh) 2006-02-22
EP1560844A1 (en) 2005-08-10
KR20050085009A (ko) 2005-08-29
MXPA05005202A (es) 2006-01-27
BR0316291A (pt) 2005-10-11
KR20050085010A (ko) 2005-08-29
NZ539999A (en) 2008-03-28
JP2006518331A (ja) 2006-08-10
MA27699A1 (fr) 2006-01-02
CO5700833A2 (es) 2006-11-30
CA2504654A1 (en) 2004-06-03
PL376967A1 (pl) 2006-01-23
US20090232847A1 (en) 2009-09-17
NZ539998A (en) 2008-04-30
RU2005113692A (ru) 2006-01-27
MA27700A1 (fr) 2006-01-02
AR041964A1 (es) 2005-06-01
ZA200503802B (en) 2006-08-30
PL376882A1 (pl) 2006-01-09
AU2003288072A1 (en) 2004-06-15
IS7830A (is) 2005-04-28
IS7831A (is) 2005-04-28
WO2004046175A1 (en) 2004-06-03
RU2323744C2 (ru) 2008-05-10
ZA200503803B (en) 2006-08-30
NO20052149L (no) 2005-07-11
JP2006524181A (ja) 2006-10-26

Similar Documents

Publication Publication Date Title
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
WO2001068117A3 (en) Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections
ATE473750T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der unterdrückung von hepatitis virus infektion
SG156652A1 (en) Yeast-based therapeutic for chronic hepatitis c infection
CY1106334T1 (el) Βελτιστοποιημενου κωδικονιου αλληλουχιες ιου θηλωματος
DE60334205D1 (en) Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
EP1200109A4 (en) USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C
AU4358701A (en) Methods of preventing and treating respiratory viral infeciton using immunomodulatory polynucleotide sequences
WO2005118626A3 (en) Peptides for inducing a ctl and/or htl response to hepatitis c virus
EA200700243A1 (ru) Способы лечения гепатита с
WO2006086188A3 (en) Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
EP1728863A3 (en) C-class oligonucleotide analogs with enhanced immunostimulatory potency
IL202978A0 (en) West nile virus vaccine
MXPA06013388A (es) Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
WO2004085633A8 (en) A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
DE602006014720D1 (de) Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
EP1613345A4 (en) COMPOSITIONS AND METHODS WITH THE RESPIRATORY SYNCYTIAL VIRUS SUB-GROUP B STAMM 9320
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
MXPA02011969A (es) Metodos para el tratamiento de padecimientos virales con il-18 y combinaciones de il-18.
TW200509964A (en) VP1 of foot-and-mouth disease virus
DE60325838D1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine
NZ512341A (en) Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments
WO2005056051A3 (en) Hepatitis b vaccines and compositions